These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 23842986)
41. Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer. Narayan V; Mamtani R; Keefe S; Guzzo T; Malkowicz SB; Vaughn DJ Cancer Res Treat; 2016 Jul; 48(3):1084-91. PubMed ID: 26639198 [TBL] [Abstract][Full Text] [Related]
42. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Herchenhorn D; Dienstmann R; Peixoto FA; de Campos FS; Santos VO; Moreira DM; Cardoso H; Small IA; Ferreira CG Int Braz J Urol; 2007; 33(5):630-8; discussion 638. PubMed ID: 17980060 [TBL] [Abstract][Full Text] [Related]
43. [EFFICACY OF NEOADJUVANT GEMCITABINE AND CISPLATIN IN THE MANAGEMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER]. Hashimoto K; Shindo T; Itoh N Nihon Hinyokika Gakkai Zasshi; 2015 Jan; 106(1):1-6. PubMed ID: 26399123 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer. Hattori Y; Fujiwara T; Hagimoto H; Kokubun H; Murata S; Makita N; Abe Y; Kubota M; Tohi Y; Tsutsumi N; Shibasaki N; Inoue K; Kawakita M; Yamasaki T Int J Urol; 2024 Oct; 31(10):1102-1106. PubMed ID: 38961545 [TBL] [Abstract][Full Text] [Related]
45. Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients. Chau C; Wheater M; Geldart T; Crabb SJ Eur J Cancer Care (Engl); 2015 Mar; 24(2):155-62. PubMed ID: 25620269 [TBL] [Abstract][Full Text] [Related]
46. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978 [TBL] [Abstract][Full Text] [Related]
47. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Aydin AM; Cheriyan SK; Reich R; Hajiran A; Peyton CC; Zemp L; Yu A; Li R; Poch MA; Spiess PE; Jain R; Zhang J; Sexton WJ; Gilbert SM Urol Oncol; 2022 Oct; 40(10):453.e19-453.e26. PubMed ID: 35811208 [TBL] [Abstract][Full Text] [Related]
48. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. Pal SK; Ruel NH; Wilson TG; Yuh BE Clin Genitourin Cancer; 2012 Dec; 10(4):246-50. PubMed ID: 22981208 [TBL] [Abstract][Full Text] [Related]
49. Systemic Inflammatory Index: A Promising Non-Invasive Marker for the Prediction of Response to Neoadjuvant Chemotherapy prior to Cystectomy. Ozcan L; Polat EC; Baran C; Boylu A; Erkoc M; Otunctemur A Urol Int; 2024; 108(3):226-233. PubMed ID: 38368856 [TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies. Cho SW; Lim SH; Kwon GY; Kim CK; Park W; Pyo H; Chung JH; Song W; Sung HH; Jeong BC; Park SH Cancer Res Treat; 2024 Jul; 56(3):893-897. PubMed ID: 38374699 [TBL] [Abstract][Full Text] [Related]
52. Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy. Amini E; Ahmadi N; Clifford TG; Hugen CM; Bazargani ST; Cai J; Miranda G; Sherrod AE; Daneshmand S; Djaladat H Int Urol Nephrol; 2019 Mar; 51(3):435-441. PubMed ID: 30706249 [TBL] [Abstract][Full Text] [Related]
54. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. Meleis L; Moore R; Inman BA; Harrison MR J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469 [TBL] [Abstract][Full Text] [Related]
56. Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy. Chen J; Miranda G; Cai J; Daneshmand S; Djaladat H Scand J Urol; 2019; 53(2-3):123-128. PubMed ID: 31081431 [No Abstract] [Full Text] [Related]
57. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer. Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021 [TBL] [Abstract][Full Text] [Related]
58. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors. Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282 [TBL] [Abstract][Full Text] [Related]
59. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762 [TBL] [Abstract][Full Text] [Related]
60. Dose dense MVAC prior to radical cystectomy: a real-world experience. Zargar H; Shah JB; van de Putte EEF; Potvin KR; Zargar-Shoshtari K; van Rhijn BW; Daneshmand S; Holzbeierlein JM; Spiess PE; Winquist E; Horenblas S; Dinney C; Black PC; Kassouf W World J Urol; 2017 Nov; 35(11):1729-1736. PubMed ID: 28625005 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]